Advertisement

Quality and Standardization for Globalization

  • Satoru Kimura
  • Yasuhide Nakamura
Chapter
Part of the Trust book series (TRUST, volume 5)

Abstract

The IMPACT did not explicitly define substandard medicines. This may be explained by the existence of the premise that “specification” is a self-evident thing. For manufacturing pharmaceutical products, there exist international concepts and norms integrated into the undertaking of Good Manufacturing Practice (GMP), which suggest the premise that if a medicine complies with the GMP, its quality will be controlled. When poor quality drugs are discussed, there is a tendency for concluding that such drugs are related to technical problems in terms of GMP, except when they involve criminal activity. The fact that modern medicines have specifications as industrial products has yielded many advantages. Specifically, drug regimens have become interchangeable beyond borders, and technology transfer has become practical, facilitating the spread of manufacturing and use of medicines across the world. Furthermore, specification and standardization of pharmaceutical products have resulted in stricter identification of disease concepts, and in more clear and precise decision-making for the indications of pharmaceuticals, which has formulated a positive cycle enabling further development of medicines. On the other hand, the spread of medicines across the world has also brought about the possibility of disseminating problems associated with product quality.

Keywords

Compatibility GMP Quality Standardization Technology transfer 

References

  1. Diamond Online. 2008. Phillip Crosby ZD (Kekkan Zero) Undo [Phllip Crosby ZD (Zero Defect Campaign)]. http://diamond.jp/ articles/-/3273. (In Japanese) Accessed 13 September 2016.
  2. GaBI. 2012. Definitions of generics. http://gabionline.net/Generics/General/WHO-definitions-of-generics. Accessed 24 June 2018.
  3. Hashimoto, Takehiko. 2015. Monozukuri no Kagakusi -Sekai wo Kaeta Hyojun Kakumei - [Science History on Manufacturing - Revolution of Standardization Which Has Changed the World-]. Tokyo: Kodansha Gakujutsubunko. (In Japanese).Google Scholar
  4. Hayashi, Takabumi, and Furui, Hitoshi. 2012. Takokuseki Kigyo to Gurohbaru Bijinesu [Multinational Enterprises and Global Business]. Tokyo: Zeimu Keiri Kyokai. (In Japanese).Google Scholar
  5. Hiyama, Yukio. 2010. Iyakuhin no Hinshitsu Kakuho to GMP [Pharmaceutical Product Quality Control and Good Manufacturing Practices]. Bulletin of National Institute of Health Sciences 128: 1–16. http://www.nihs.go.jp/library/eikenhoukoku/2010/001-016.pdf#search=%27%E6%AA%9C%E5%B1%B1%E8%A1%8C%E9%9B%84+%282010%29%2C+%E5%8C%BB%E8%96%AC%E5%93%81%E3%81%AE%E5%93%81%E8%B3%AA%E7%A2%BA%E4%BF%9D%E3%81%A8GMP%2C%27. (In Japanese) Accessed 1 Sept 2018.
  6. JPMA. 2010. PIC/S no Gaiyo ni Tsuite [Overview on PIC/S]. http://www.who.int/about/agenda/en/. (In Japanese) Accessed 14 September.
  7. Kunits, S.J. 1988. Hookworm and Pellagra. Journal of Health and Social Behavior 29.Google Scholar
  8. Miichi, Masatoshi, Saito Osamu, and Wakimura Kohei. 2001. Shippei, Kaihatsu, Teikokuiryo—Ajia ni okeru Byoki to Iryo no Rekishigaku [Diseases, Development and Imperial Medication—History on Diseases and Medication in Asia]. Tokyo: Tokyo University Press. (In Japanese).Google Scholar
  9. Minato, Kazuki. 2007. Indo Seiyaku Sangyo -Hatten no Seidoteki Haikei to TRIPS Kyoteigo no Henka [Pharmaceutical Industry in India: The Institutional Background of Development and Changes after TRIPS Agreement]. ed. Kubo Keisuke, 21–54. In Nihon no Jenerikku Iyakuhin Shijo to Indo, Chugoku no Seiyakusangyo [Generic Drug Market in Japan and Pharmaceutical Industry in India and China]. Chiba: IDE-JETRO. (In Japanese).Google Scholar
  10. Nasdaq. 2016. Generic Drugs: Revolutionary Change in the Global Pharmaceutical Industry. https://www.nasdaq.com/article/generic-drugs-revolutionary-change-in-the-global-pharmaceutical-industry-cm576603. Accessed 14 Aug 2018.
  11. Tadara, Kozo, and Toshiyuki Takizawa. 2011. Koshu Eisei [Public Health]. Tokyo: Foundation for the Promotion of the Open University of Japan. (In Japanese).Google Scholar
  12. Taguchi, Gen-ichi. 1993. Hinshu to Hinshitsu [Species and Quality]. Quality Engineering Forum 1 (4): 2–6. https://www.jstage.jst.go.jp/article/qes/1/4/1_2/_pdf. (In Japanese) Accessed 24 June 2018.
  13. Takechi, Kyozo. 2011. GMP no Hoseika to Naraken Seiyaku Sangyoh –Kigyohsha Shiteki Siten kara- [Legislation of GMP and the Pharmaceutical Industry in Nara Prefecture: From Viewpoint of Entrepreneurial History]. Journal of Business Studies 57(3): 59–126. Kindai University Academic Resource Repository. https://kindai.repo.nii.ac.jp/?action=pages_view_main&active_action=repository_view_main_item_detail&item_id=11778&item_no=1&page_id=13&block_id=21. (In Japanese) Accessed 1 Sept 2018.
  14. Weinberg, G.M. 1992. Quality Software Management: Volume 1 Systems thinking. Trans. New York: Dorset House Publishing.Google Scholar
  15. WHO. GMP Question and Answers. http://www.who.int/medicines/areas/quality_safety/quality_assurance/gmp/en/. Accessed 2 October 2016.
  16. Yamane, Hiroko. 2008. Chiteki Zaisanken no Gurohbaruka -Iyakuhin Akusesu to TRIPS Kyotei- [Globalization of Intellectual Property Rights -Access to Medicines and TRIPS Agreement-]. Tokyo: Iwanami Shoten. (In Japanese).Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Satoru Kimura
    • 1
  • Yasuhide Nakamura
    • 2
  1. 1.Department of Reference StandardsPharmaceutical and Device Regulatory Science Society of JapanOsakaJapan
  2. 2.School of Nursing and RehabilitationKonan Women’s UniversityKobeJapan

Personalised recommendations